Quick Summary — BMRN scores higher on quality with 9.2/10 vs BHVN's 3.8/10. BHVN trades at $10.13 while BMRN trades at $53.32. Both analyzed daily using SEC EDGAR data across 13 institutional models.
BMRN scores higher with a 9.2/10 quality rating vs BHVN's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $10.13, BHVN trades +72.8% above its Bayesian DCF fair value of $2.75, while BMRN at $53.32 trades +46.5% above its estimate of $28.52. BHVN shows a wider gap between price and intrinsic value.
BHVN earns a Quality of Company score of 3.8/10 compared to BMRN's 9.2/10. This is a significant quality gap — the higher-scoring company demonstrates materially stronger fundamentals across profitability, growth consistency, and balance sheet health. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
Review the value trap analysis for both BHVN and BMRN to assess whether apparent undervaluation reflects genuine opportunity or hidden fundamental risk.
Both BHVN and BMRN operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare BHVN vs BMRN differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.